These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 18199869

  • 1. Clinical decisions. Management of type 2 diabetes.
    Goldberg RB, Holman R, Drucker DJ.
    N Engl J Med; 2008 Jan 17; 358(3):293-7. PubMed ID: 18199869
    [No Abstract] [Full Text] [Related]

  • 2. Which oral agent to use when metformin is no longer effective?
    Bannon M.
    QJM; 2011 Mar 17; 104(3):183-4. PubMed ID: 21330402
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE.
    Endocrinol Metab Clin North Am; 2007 Dec 17; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical decisions. Glycemic management in a patient with type 2 diabetes.
    Hirsch IB, Molitch ME.
    N Engl J Med; 2013 Oct 03; 369(14):1370-2. PubMed ID: 24088099
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA.
    Diabetes Obes Metab; 2009 May 03; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb 03; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V, Wazny LD, Raymond CB.
    CANNT J; 2012 Feb 03; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract] [Full Text] [Related]

  • 13. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Seufert J.
    Fundam Clin Pharmacol; 2009 Dec 03; 23(6):651-67. PubMed ID: 19469803
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes].
    André P.
    Rev Epidemiol Sante Publique; 1999 Mar 03; 47(1):93-5. PubMed ID: 10214683
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 03; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.